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Lung cancer is one of the most common types of neoplasm and is a leading cause of 
death in Canada. Accurate early diagnosis is key to the effective treatment of the disease, 
however the current means to do so, such as Computed Tomography diagnostic imaging, 
are costly, invasive, and not practical for routine use. The detection of volatile cancer 
biomarkers in breath represents an attractive non-invasive means to diagnose the disease. It 
is unclear, however, which, if any, breath chemicals have diagnostic utility. In this thesis I 
used Selected Ion Flow Tube Mass Spectrometry (SIFT-MS), a trace gas analytic method 
to (a) identify potential volatile cancer biomarkers in blood, and (b) investigate whether 
these markers are present in breath. Potential biomarkers were identified by comparing 
products ions formed in the reaction between hydronium (H3O+) and nitronium (NO+) 
precursor ions and trace gases present in the headspace of plasma obtained from patients 
with breast cancer, colorectal or lung cancer, and healthy controls. Using this approach 
product ions of interest were identified which derive from a wide range of chemical classes 
including aldehydes, acids, alcohols and sulphides, including some which have been 
identified previously by other investigators. Many of these ions could be quantified in the 
breath of healthy controls and therefore be suitable for quantification by breath analysis.  
The production rate of most of these ions was, however, poorly correlated between those 
formed in the reactions between nasal breath and those formed in reactions with blood 
headspace, even when using in samples collected and analysed simultaneously from the 
same participants.  The lack of correlation suggests that the breath trace gases from which 
these product ions are formed are not dependent on the blood concentration of the same 





biomarkers may be found in the bloodstream, breath analysis is not a suitable means to 
non-invasively detect these cancer markers, in particular cancers of tissues other than those 
found in the airway. On the other hand, my data suggests that the detection of airway 
disease, including that of lung cancer, may be suitable candidates for the diagnosis and/or 





















Chapter 1: Introduction 
1. Background 
Cancer is a class of disease characterized by uncontrolled cell division and the 
invasive spread of cancer cells1 which if left untreated can lead to ill-heath and death. In 
2011 almost 29.9 % of deaths in Canada were due to cancer. In addition, in 2015 around 
196,900 new cancer cases occurred in Canada while the disease led to 78,000 deaths.2 The 
risk of developing cancer is increased by extrinsic factors, for example, tobacco use and 
certain dietary habits1, and intrinsic factors such as inherited susceptibility genes. Indeed, in 
the USA in 2015, approximately 171,000 of the evaluated 589,430 cancer deaths were 
attributed to tobacco smoking. Similarly, the World Cancer Research Fund has estimated 
that up to 33% of cases in the USA are associated with obesity, poor diet, and a sedentary 
life style.1 These components may act either together or in succession to bring about 
disease in a complex etiological process that hampers screening and diagnosis. On the other 
hand, ten or more years frequently go between the initiating event and clinical presentation 
allowing for effective treatment to occur if the tumour is detected, although it should be 
noted that some aggressive tumors progress much more rapidly.1  
1.1. Lung cancer 
Out of all types of cancer lung cancer has the highest worldwide incidence. 
According to a recent report, lung cancer caused 158,040 deaths in the USA during 2015, 
comprising 27% of all cancer deaths. The high prevalence of lung cancer is primarily due 
to the environmental exposure to substances such as asbestos, arsenic and polycyclic 




factors being so common lung cancer is likely to remain a significant global mortality risk 
for the foreseeable future.6  
The 5 year mortality rate of lung cancer from the time of its presentation is very high, 
estimated to be about 85-90% even though surgical and chemotherapeutic treatment is 
available and commonly used.7 Encouragingly, many reports suggest that if the lung cancer 
is detected at its early stage it can be easily treated.8,9 However, there are limited techniques 
available such as Computerized Tomography (CT) Scan or, Magnetic Resonance imaging 
(MRI) which made difficult to detect which are generally too costly to be used as a general 
screening tool. However, early detection is made difficult due to the limited techniques 
available such as Computerized Tomography (CT) Scan or, Magnetic Resonance imaging 
(MRI) that which are generally too costly to be used as a general screening tool as 
described below.10 
1.2 The challenges of early and timely diagnosis of lung cancer.  
Patients with lung cancer are frequently symptomatic for a long time before they seek 
medical attention.11 They generally present with numerous symptoms including coughing, 
blood or hemoptysis, shortness of breath or altered breathing, wheezing, chest pain, weight 
loss, and fatigue.11–13 The fact that patients frequently ignore the initial symptoms 
obviously delays diagnosis but also worsens the prognosis, whereas enhancing patient 
awareness of lung cancer symptoms results in earlier stage diagnosis.11,14 Indeed, early 
diagnosis generally increases the effectiveness of treatment, reducing mortality and 
morbidity, since the tumour can be treated at an earlier stage of the disease when it has 




accurate diagnosis aids in the determination of a course of action, in terms of selecting a 
treatment, and increases the treatment’s effectiveness14. Ideally a diagnostic test should be 
accurate, cause no discomfort or risk to health, and be non-invasive.15  
Since the early 20th century, there are various techniques have been used for 
detecting the presence of lung cancer, including chest radiography, histological assessment, 
and sputum cytology. These tools are not suitable for population-based screening due to the 
risk associated with these invasive procedures such as radiation exposure, and/or the 
involvement of technically difficult and expensive techniques such as gas chromatography 
mass spectrometry. As a result, they are not widely used for the early detection of cancer.16 
Morphological abnormalities such as lesions have also been used to assess the disease, but 
this is usually done when a person has passed the early stage (stage-1) of the cancer when 
the disease is most amenable to treatment. Indeed, the biopsy of tissues, such as for 
suspected basal cell hyperplasia and squamous metaplasia, types that are increased in 
smokers, are usually only used in the late stages of lung cancer and have, at best, limited 
usefulness.17 
Most recently, CT scans have proven to be more useful for the early diagnosis of 
lung cancer compared to traditional radiography. In CT X-rays are used to form 3 
dimensional images of the body, which assists in the detection of small early stage tumours. 
Recently, CT has being augmented by Positron Emission Tomography, which increases the 
diagnostic accuracy. An advanced form of CT imaging called ‘spiral’ or ‘helical’ CT scan, 
which provides more accurate images of internal organs, have allowed for the detection of 




it is expensive, invasive and associated with some risk due to radiation exposure which 
makes it unsuitable for the sort of regular ‘health check’ which would revolutionise the 
early diagnosis of lung cancer and allow treatment to occur in its early stages.  There is 
therefore a need for new diagnostic techniques to be developed, such as those utilising so-
called cancer ‘biomarkers’, particularly when used as pre-imaging screening test to select 
those who should undergo further testing.8   
 
1.3 Biomarker based cancer tests.  
A biomarker can usefully be defined as a molecule that is associated with a 
particular physiological state, including pathological disease states; for example, plasma 
glucose concentration is a biomarker of diabetes. Ideally disease biomarkers would 
specifically and sensitively reflect a pathological state which could be utilized for 
diagnosis, estimating prognosis, treatment selection, and/or for monitoring the efficacy of 
treatment.18,19 While biomarker development for clinical use is not without difficulties they 
have great appeal given they are relatively simple and inexpensive to use. Volatile 
compounds found in the breath are a particular type of biomarker that are particularly 
attractive since they can be quantified using an entirely non-invasive process.  Specifically, 
‘breath analysis’ involves analyzing the chemical composition of trace gas volatile 
inorganic and organic compounds in the exhaled breath as the end products of metabolic 
processes which may be able to tell us something about physiological and pathological 
states. The latter could well from the basis of a diagnostic test for cancer and other diseases 





1.4 Volatile Organic and Inorganic Compounds as a type of biomarker.  
Volatile Compounds (VC) have a high vapour pressure at room temperature under 
normal pressure conditions and therefore exist, to varying degrees, in the gas phase.  They 
can be organic aliphatic or aromatic compounds, or inorganic such as nitric oxide.  
Consisting of nitrogen, oxygen, carbon dioxide, inert gases and water, breath also consists 
of approximately 1000 trace VC. The concentrations of VCs in the breath range from parts 
per million (PPM) to parts per trillion (PPT) with some of the most abundant being 
isoprene, acetone, ammonia, and propanol.20 It has been proposed that VC can be used as 
disease markers which have the potential to form the basis of diagnostic tests, particularly 
exhaled breath, with a growing body of evidence supporting that claim (see Section 1.7).20 
Their interpretation is complicated, however, by the fact that the compounds one breathes 
out have a number of sources of origin all of which can be present simultaneously.  20  
 
1.5 Sources of VC in breath.  
 
Many of the VC in the breath are exogenous in origin, that is, what is breathed out 
derives from what is breathed in. Indeed, atmospheric air has been identified as the main 
source of breath VC originating from both natural and human-made sources.21 For 
example, chemicals including trichloroethene, toluene and tetrachloroethylene are 
commonly found in the bloodstream but are thought to be exclusively exogenous in 
origin.21 Aside from occupational chemical exposure applications such exogenous 
compounds are not of great interest as biomarkers.  Endogenous VC, on the other hand, 
derived from metabolic processes taking place in the body including the airways, 




not be present at all in ambient air.  This is not true, however, for most common breath VC 
which do occur in ambient air, making the interpretation of breath concentrations difficult. 
For example, lipid peroxidation of unsaturated fatty acids produces volatile alkanes (ethane 
and pentane) and aldehydes (propanal and hexanal)22, which are breathed out but also have 
exogenous sources such as the burning of hydrocarbons or are released by plants.23 Another 
abundant breath gas, acetone is created by hepatocytes via decarboxylation of excess 
acetyl-CoA.22 but is also a very commonly used solvent.  Even isoprene, which is formed 
during the metabolism of mevalonate during cholesterol biosynthesis, is found exogenously 
to varying extents.23 Adding to this complexity endogenous compounds are not always 
formed in the patients’ own tissues. For example, ethanol and methanol in the breath is 
derived from intestinal bacterial flora.23 Sulphur containing compounds in the breath can 
emanate in the liver and lungs, but predominantly derived from the gastrointestinal tract 
and oral cavity.24 Similarly while ammonia in the breath can indicate kidney failure, the gas 
mostly originates from microorganisms in the mouth.25 Moreover, the relationship between 
the VC in each body “compartment” (such as the circulation and various body tissues) is 
unclear even though much of the diagnostic potential of breath testing relies on there being 
a direct relationship between VC in the diseased tissue and VC in breath.  It is therefore 
difficult to determine the actual source of breath VC and, hence, what any changes in their 
concentration may mean.  In this study I minimised the confounding effect of ambient air 
by collecting breath samples in the same location throughout.  I also collected breath in a 
manner which minimised the contribution of VC emanating from mouth microorganisms. 




and will have to be taken into account when breath analysis is used in ‘real world’ clinical 
applications. 
 
1.6 Use of VC in diagnostic tests.  
In order to use VC as a clinical tool, the VC profiles (also known as volatomes) of 
healthy and unwell individuals, need to be well defined. Additionally, the source of each 
VC needs to be studied. As mentioned above, exhaled air is a blend of various sources of 
air.  Specifically these include alveolar air, derived from lung and non-lung sources, dead 
space air in the airways of the lung, and ambient air. Dead space air includes the mouth, 
bronchiole, nose, and pharynx all of which can possess VC.26,27 As such the manner in 
which breath is collected is of importance. Breath samples are collected from participants 
in different ways such as capnography, direct on-line measurements, or in Tedlar bags.26–28 
These collection techniques vary in terms of the contribution of dead space air to the 
volatome. When one is interested in VC which do not originate within the deadspace air of 
the airways, nasal air is preferable to collect, compared to that emanating from the mouth, 
since it minimizes the contribution of oral cavity microorganisms. Indeed, nasal and mouth 
air can contain markedly different VC concentrations. For example, Schmidt et al. reported 
that the concentration of ammonia in the mouth was approximately 20-fold higher than 
nasal air since most ammonia breathed out of the mouth is generated on the dorsal surface 
of the tongue.29 Even using nasal air we cannot, of course, be certain of the actual tissue 





1.7 Use of VC as disease biomarkers.  
To date the only ‘breath test’ in common clinical practice is used to diagnose the 
presence of Helicobacter pylori in the stomach.  In that test ingestion of isotopically 
labelled urea is catabolized by urease present in the bacterium leading to the release of 
labeled carbon dioxide, which can be detected in the breath.23 Another less common, but 
commercialized application, measures nitric oxide as a measure of airway inflammation20, 
while other applications are still in development such as the detection of hydrogen cyanide 
as a marker of lung Pseudomonas aeruginosaaeroginosa infection.30 The catabolism of 
isotopically labelled erythromycin to carbon dioxide has been used to estimate the 
clearance rate of the chemotherapeutic drug docetaxel as a means to detect hypo-
metabolisers who will experience severe toxic reactions.31 Finally, the catabolism of 
glucose to hydrogen has been assessed using a breath test to determine bacterial growth 
rates in the gastrointestinal tract as may occur in several bowel disorders.32  
 
1.8 Use of VC as diagnostic or screening test for cancer. 
Encouraged by such applications many researchers have attempted to identify 
biomarkers of lung cancer as summarized in Table 1. As can be seen there have been a 
large number of potential biomarkers identified although none have been developed into a 
routinely used clinical test.  The most developed, from a commercial perspective at least, 
emanate from the research group lead by Philips who have made use of Gas 
Chromatography Mass Spectrometry (GC/MS) to identify lung cancer markers (mostly 
alkanes) and have reported that these markers can detect lung cancer with an approximate 




Table 1. Various volatile organic compounds of biomarkers for lung cancer in literature.  







S, Hpp, Hm, D, Pb, U, C, Cmp, Mt, B, Bt, Ibm, O, 
He, No, Hp, Bd, Hpd, Hx, Cy, Bm, Hl.  LC 60 67 GC/MS 100 81.3 
33 
An, OT, C. LC 28 60 Gas Sensor array 85 100 
37 
Pa, But,Pt, Hx, Hl, Oc, N  NSCLC 40 68 SPME-GC/MS NC NC 38 
S, D, I, B, U, He, Hx, Pb, Tb, Hl, Mc. LC 29 >50 SPME-GC/MS 86 69 16 
Bu, Mo, E, Ac, Pn, I, Pr, Ds, Cd, B, T LC 14 64 Sensor array 71 92 39 
Bu, T3m, T7m, O4m, H3m, Hp, H2m, Pn, D5m LC 178 64 GC/MS 90 82 34 
Cdd, Pdt, Ba, Pam, Dd, Cdb, Bo, Fu, Bdl, Pd, Tc, Hid, Pr, Dm, 
Bade, Hd. LC 193 66 GC/MS 85 80 
35 
I, Mp, Pn, Eb, X, Tb, T, B, Hp, D, S, O, Pen NSCLC 36 67 GC/MS 72 94 40 
F, Pr, Ac, I, Ot LC 17 62 PTR/MS 54 99 41 
Pr, Po,Ett, Pmm, Pmo, Hxd, Dh, Hxm, Hid, Cp, Bht, Cmt, Pm, 
Imoh, Ii, Tu, Tpd, Ba, Bnda, Patc, Pam, Tet, Ben, Cyd, Fu, Bc, 
Bcp, Atp, Ae, Bee. 
LC 193 NS GC/MS 85 81 36 
Abbreviations: Where LC: Lung Cancer, NSCLC: Non-Small Cell Lung Cancer, n: number of patients, Age: Average Age, NC: Sensitivity and Specificity  
are not calculated.  NS: Not stated. 
Biomarker abbreviations: Ac: Acetone (3). Ae: 2-ethyl-9,10-anthracenediol, (1). An: Aniline (1). Atp: 1,2,3,4-terahydro-9-propyl-anthracene,. (1). B: benzene (4). Ba: 
Ethyl-4-ethoxy benzoate(2). Bc: 1,1-(1,2-cyclobutanediyl)bis-,cis-benzene, (1). Bd: 1,4-dimethyl-benzene, (1). Bt: 1,2,4-trimethyl-benzene, (1). Bo: 1-oxybis-benzene (1). 
Bu: Butane (2). Bm: 1-methylethenyl-benzene, (1). Ben: Benzophenone (1). Bade: Diethyl benzene-1,2-dicarboxylate (1). Bdl: 2,2-diethyl-1,1-Biphenyl, (1). Bee: 1,1-
ethylidene-bis[4-ethyl]-benzene, (1). Bep: 1,1-[1-(ethylthio)propylidene]bis-Benzene, (1). Bht: 7,7-trimethyl-(1S)-bicyclo[2.2.1]heptan-2-one, , (1). But: Butanal, (1). 
Bnda: 5-(Ethoxycarbonyl)bicyclo[3.2.2]nonane-1-carboxylic acid (1). C: methyl-cyclopentane (2). Cd: Carbon disulfide (1). Cp: Camphor (1). Cy: cyclohexane (1). Cdd: 
1,5,9-trimethyl-1,5,9-Cyclododecatriene, (1). Cdb: 2,5- 2,6-bis (1,1-dimethylethyl)-cyclohexadiene-1,4-dione, (1). Cmp: 1-methyl-2-pentyl-Cyclopropane, (1). Cmt: α,α-4-
trimethyl-3-cyclohexene-1-methanol (1).Cyd: 2,6-bis(1,1-dimethylethyl)-4-ethylidene-2,5-cyclohexadien-1-one, (1). D: decane (3). Dd: 10,11- dihydro-5H-dibenzo-(B,F)-
azepin (1). Dh: 5,5-dimethyl-1,3-hexadiene (1).Dm: 4-methyl-decane, (1). DS: dimethyl sulfide (1). E: ethanol (1). D5m: 5-methyl-decane (1). Eb: Ethylbenzene (1). Ett: 
1,1,2-trichloro-1,2,2-trifluoro-ethane (1). F: formaldehyde (1). Fu: 2,5-dimethyl-furan, (2). Hd: 2,5-dimethyl- 2,4-hexanedione, (1). He: 1-hexene (2). Hl: Heptanal (3). 
Hm; ,2-methyl heptane (1). Hp; 1-heptene (3). Hx: Hexanal (3). Hpd: 2,4-dimethyl-heptane, (1). Hpp: 2,2,4,6,6-pentamethyl-heptane, (1). Hid: 2,3-dihydro-1,1,3-
trimethyl-3-phenyl-1-H-indene, (2). Hxd: 2,3-hexadiene (1). Hxm: 2-methyl-3-hexanone, (1). H3m: 3-methyl-hexane, (1).  H2m: 2-methyl hexane, (1). I: isoprene (4). 
Ibm: 1,3-butadiene, 2-methyl-isoprene (1) Imoh: 5-isopropenyl-2-methyl-7-oxabicyclo[4.1.0]heptan-2-ol (1). Ii: a isomethyl ionone (1). Mc: Methyl cyclopropane (1), Mt: 
trichlorofluoro-methane, (1). Mp: 2-methyl-pentane (1). Mo: methanol (1). N: nonanal (1). No: 3-methyl-nonane, (1). O: 3-methyl-octane,)(2). Oc: Octanal (1). OT: o-
toluidine (2). O4m: 4-methyl-octane, (1).  Pa: propanal (1). Pd: 2,4-dimethyl-3-pentanone  (1). Pb: propyl benzene (2). Pm: p-menth-1-en-8-ol (1). Pn: pentane (2). Po: 4-
penten-2-ol (1). Pr: propanol (4). Pt: pentanal (1). Pdt: 2,2,4-trimethyl-pentan-1,3-dioldiisobutyrate, (1). Pam: propanoic acid, 2-methyl-, 1-(1,1-diamethylethyl)-2-methyl-
1,3-propanediyl ester (2). Patc: propanoic acid, 2,2,4-trimethyl-3-carboxyisopropyl, isobutyl ester (1). Pen: pentamethylheptane (1). Pmm: 2-methoxy-2-methyl-propane , 
(1). Pmo: 1-(methylthio)-(E)- (1)1-propene,. S: styrene (3). T: toluene (2). Tb: 1,2,4-trimethyl benzene (2). Tc: trans-caryophyllene (1). Tu: 2,2,7,7-
tetramethyltricyclo[6.2.1.0(1,6)]undec-4-en-3-one (1). T3m: 3-methyl tridecane, (1). T7m: 7-methyl-tridecane, (1). Tet: 1,2,4,5- 3,3,6,6-tetraphenyl-tetroxane, (1). Tpd: 




Many of the cancer biomarker studies has a low sample size, which reduces their 
statistical power and hence the robustness of their findings, possibly explaining the huge 
variety of potential biomarkers explored.  Some putative markers have been reported in 
multiple studies however with these being listed in Table 2.  Compounds in diverse classes 
such as ketones, aldehydes, aromatic compounds, alcohol, alkenes, and particularly alkanes 
have been identified in multiple studies from multiple research groups adding credence to 
their veracity as actual markers.  On the other hand, for many of these compounds, such as 
toluene and methyl-cyclopentane, their biological source remains obscure thereby 
decreasing their plausibility as biomarkers, while others, such as propanol and acetone, are 
well characterised metabolically16,33–41 and hence are somewhat more credible biologically 
as cancer markers. 
A second, arguably more important problem with the current literature, is that all 
previous studies, including those conducted by the Phillips group looked at symptomatic 
patients only.  This raises the question of whether the marker is actually present in the pre-
symptomatic period when they would be most useful, or whether they are mere 
‘epiphenomena’ occurring subsequent to the primary pathophysiological process (such as 
the cachexia which occurs frequently in later stage cancer patients). This would require 
researchers to conduct so-called prospective investigations in either general or ‘at risk’ 
populations to determine if any of the potential biomarkers identified can detect lung cancer 
in the pre-symptomatic stage of the disease, a requirement for any useful diagnostic or 
screening test.  Prospective studies are very expensive to perform given they require large 
sample sizes and long follow-up times to achieve the statistical power necessary to 




literature.  A less costly alternative aimed at generating evidence that would justify the cost 
of a prospective analysis, is to use a cross-sectional design that includes multiple cancer 
types. Specifically, a marker, which occurred in a single type of cancer is more likely to be 
a primary marker, at the very least being one worthy of the time and expense of undertaking 
a large prospective study. In my study I will therefore use a larger sample size than many 
studies and include several different types of cancer (lung, colorectal, and breast).  
1.9 Selected Ion Flow Tube Mass Spectrometry (SIFT/MS). 
The gold standard for VC analysis is GC/MS which has been used in many cancer 
biomarker identification studies.34,35,37,40 GC/MS is however technically demanding and 
costly. Other techniques have been developed including electronic sensors, ions mobility 
spectrometry, and various mass spectrometric techniques all of which avoid 
chromatographic separation and are generally technically easier, cheaper, and faster to 
perform. One such technique, Selected Ion Flow Tube Mass Spectrometry (SIFT-MS), will 
be used in this study. This method quantifies trace gases using chemical ionization by 
reacting charged precursor ions (usually H3O+, NO+ or O2+)42 with the gases in a breath 
sample. The product ions produced in this reaction are characteristic of the VC present, 
while their rate of formation allows absolute quantification to be performed, that is, without 
the need for calibration standards.  
The workings of the SIFT-MS are shown in Figure 1. Precursor ions are produced 
from low pressure water vapour using a microwave.  The desired precursor ions are then 
selected by a quadrupole mass filter and carried in a stream of helium gas into the flow tube 
where they mix with the gas sample introduced into the flow tube using negative pressure. 




which are then quantified using a quadrupole mass spectrometer and photomultiplier 
combination.  Once the rate of reaction between the precursor ion and trace gases is known, 
the absolute concentration of the gas can be calculated without the need for calibration 
standards. Importantly, the availability of three precursor ions can help differentiate 
between isomeric and isobaric compounds which generally do not produce the same product 
ions with all 3 precursors given that the H3O+ precursor usually reacts by proton transfer, 
while the NO+ precursor reacts to form charge transfer products, including the molecular 
ion, or NO+ -adducts depending on the ionisation energy of the trace gas.42 The more 
energetic O2+· reacts similarly to NO+ for many compounds, but produces more 
fragmentation product ions.42 The instrument can be operated in Full Scan (FS) mode over a 
range of m/z values (generally 10 – 200 m/z) which is useful for determining which VC are 
present in a sample but provides low measurement precision due to the short length of time 
that each m/z value is quantified.  This lack of precision can be overcome by using Multi-
Ion Monitor (MIM) mode which quantifies a much more limited range of ions for a longer 
period of time thereby increasing the measurement precision of trace gases selected a 
priori.42 Typical data produced using both FS and MIM modes are illustrated in Figures 2 










Table 2: Volatile compounds with altered abundance in human with lung cancer 
reported in more than one study.    
 
Name of compounds Times 
reported  
  
Expected ions (m/z) 
 
Reference 
H3O+  NO+  
Acetone 2 59,77 88 39,41 
Benzene 4 79 78 16,33,39,40 
Butane 2 No reaction No reaction 34,39 
Decane 3 161 141 16,33,40 
Ethyl-4-ethoxy benzoate 2 Unknown Unknown 35,36 
2,5-dimethyl-furan 2 Unknown Unknown 35,36 
Hexene 2 85 86 16,33 
Heptanal 3 97, 115 113 16,33,38 
Heptene 3 Unknown Unknown 33,34,40 




2 Unknown Unknown 35,36 
Isoprene 4 No reaction 66, 68 16,36,39,40 





2 Unknown Unknown 31,36 
Pentane 3 No reaction No reaction 34, 39,40 
Propanol 4 43, 61, 79, 97 59 35, 36, 39, 41 
Styrene 3 105 104 16,33,40 
o-toluidine 2 Unknown Unknown 37,41 
Toluene 2 93 92 39,40 
Methyl-cyclopentane 2 Unknown Unknown 33,37 
1,2,4-trimethyl benzene 3 120 121 16,33,40 
Undecane 2 161 141 16,33 
The compounds listed in Table 1 which appear in more than one report in the literature are described.  The 







Figure 1: Schematic diagram of the Selected Ion Flow Tube Mass Spectrometer (SIFT-MS) used in this study.  Some typical reactions 









Figure 2. Sample of a mass spectrum produced using the FS mode of the SIFT-MS using 
the H3O+ precursor. Ion count rates, c/s (vertical axis),, plotted against that mass-to-
charge ratio, m/z. The numbers over the peaks give the m/z value, the most abundant 
being the H3O+ ion (m/z 19) and its mono (m/z 37), di (m/z 55) and tri (m/z 73) hydrates.  
















Figure 3. Illustration of the MIM mode of the SIFT-MS. Product ion count rates 
have been converted to concentrations using reaction rate constants to calculate absolute 
amounts of the gas in a unit time, with knowledge of the sampling flow rate being used 
to convert those to concentrations.  The concentration of each compound is averaged 
over a selected region of data and displayed by the software.  The most abundant 
compound shown is water vapour which varies as different samples are introduced into 





The purpose of this study was two-fold. Firstly, the blood headspace volatome 
from patients with lung, breast and colon cancer and healthy controls were compared in 
order to identify potential cancer biomarkers. Secondly, the abundance of these putative 
biomarkers was measured in breath, and the relationship between blood and breath 






































I expect that (i) the volatome of blood headspace will differ between cancer and 
control groups, that is that the concentration of gases present in blood headspace will differ 
between participant groups, (ii) that one or more of the VC changes in abundance will be 
limited to a single type of cancer, and (iii) that these VC will be present in breath as well as 






















4. Materials and Methods 
4.1 Participants.   
The test populations for biomarker screening (study #1) included 390 participants - 287 
cancers patients (112 of patients with breast cancer, 78 of patients with colorectal cancer, 97 of 
patients with lung cancer) and 103 healthy controls. Plasma samples had previously been 
collected and were made available to me under the existing consent which allowed for the 
analysis of biomarkers related to cancer (TBRHSC REB Approval 2004266).  Due to plasma 
sample volume limitations the FS and MIM studies analyzed had to be conducted using different 
participants.  A summary of the characteristics of the patients is shown in Table 3.  The groups 
were not age matched (the control group was significantly (P < 0.05; post-ANOVA Tukey test) 
younger than each of the patient groups), nor sex-matched (the breast cancer group was all 
female which was not the case for the other groups). Further, the two analyses, termed FS and 
MIM in the Table (see below for further details) were not conducted using the same participants 
due to sample limitations. 
 Volunteers for the study comparing breath and blood (study #2) were recruited by 
advertisement under a protocol approved by the LU REB (REB Approval # 074 15-16).  After 
giving informed consent demographic information, tobacco use, and health information were 
collected.  No participants had a current or previous diagnosis of cancer and were otherwise 




Table 3: Participant characteristics for study #1.  
 
Variable 
Control n=103 Breast n=112 Colorectal n=78 Lung n=97  
FS MIM FS MIM FS MIM FS MIM 
Sample size 50 53 50 62 35 43 42 55  
Age (mean ± SD) 44 ± 141 46 ± 131 65 ± 12 66 ± 13 73 ± 12 71 ± 11 70 ± 10 70 ± 9 
Sex (M, F) 11/39 9/44 0/50 0/62 15/20 23/20 19/23 22/33 
Abbreviations: FS = full scan, MIM = multiple ion monitoring (see Section 1.10).  M = male, and F = female. 
Participants were in stage II and III of their disease (cancer spread to nearest (II) or further (III) lymph nodes).  1 
one-way ANOVA analysis showed a significant difference between groups for FS (F3,173= 53.0; P < 0.001) and 
MIM (F3,173= 52.0; P  < 0.001) study groups with post-hoc Tukey tests indicating that the Control group differed 




Table 4: Participant demographics for study # 2. 
 
Participants Healthy controls 
Sample size 30 
Age (mean ± SD) 26.5 ± 3.77 
Sex (M, F) 15 / 15 














4.2 Breath collection (study #2) 
Breath was collected in bags made from poly vinyl fluoride (Tedlar) film (SKC Inc, 
Eighty Four, PA, USA) inflated and deflated with N2 gas (99.99% purity) three times before 
use to remove residual volatiles emanating from the bag material. All analyses of breath took 
place within 2 hours of collection. Participants were asked to sit and relax for 3 minutes and 
breathe through their nose. Then they were asked to inhale fully through their nose, hold their 
breath for 5 seconds, and then exhale completely in the bag via disposable poly tetra fluoro 
ethylene (PTFE) tube.  The first 5 seconds of exhalation were vented since this represents 
mainly bronchiolar tidal air, air more heavily contaminated with ambient trace gases, with the 
remainder being alveolar air, air which is closer to equilibrium with bloodstream VC.  If the 
collected volume was not sufficient, participants were asked to repeat the procedure until the 
desired volume was attained. After that the bag was sealed using the PTFE valve integrated into 
the bag and taken to the laboratory for analysis. A bag of ambient air was collected at the same 
time using a sampling syringe.  In the laboratory the bag was heated to human body 
temperature (37°C) for 20 minutes in an incubator to volatilize any condensed chemicals  
 
4.3 Blood collection (study #2) 
Blood was collected by a licenced phlebotomist. 6 ml of blood was withdrawn from the 
antecubital vein from a seated subject using a needle and vacutainer combination containing the 
anticoagulant ethylenediaminetetraacetic acid (EDTA).  Blood samples were placed on ice and 
transferred to the lab.   A 500µl aliquot of blood from the 6ml into a vacutainer transferred into 
a 250 ml flask, the flask incubated at 37°C for 10 minutes, and headspace gases analysed.  All 





The SIFT-MS analysis was conducted using a profile 3 SIFT-MS Instrument 
(Instrument Sciences, UK) utilizing the H3O+, NO+ and O2+ precursor ions as required.  The 
flow tube pressure used was approximately 1 Torr and the temperature approximately 27 °C in 
all experiments, reaction conditions which are typical of other studies in the literature. The 
sample gas inlet temperature used was at 100 °C chosen to prevent volatile chemical 
condensing in the sampling line (particularly that of water vapour), and the sampling rate used 
was 0.2ml/s. The instrument was allowed to stabilise for between 30 minutes and 1 hour before 
tuning of the mass filter and source to optimise pre-cursor ion count rates and ion purity by a 
combination of changing the ion source pressure, altering the injected m/z setting, or altering 
the ion energy setting of the mass filter. Moreover, the mass resolution and mass precision for 
the downstream mass spectrometer was routinely checked. The selected precursor ions made up 
over 99% of total precursor ions, and precursor ions count rates were approximately 800,000 
for H3O+ (including hydrates), and 600,000 for NO+. Product ion count rates were corrected for 
diffusion loss. Analysis breath and blood samples proceeded in two ways: (i) full scan (FS) 
mode generates mass spectrum with each m/z quantified for a short period of time with 
resulting low measurement precision particularly of low abundance ions, and (ii) multiple ion 
monitoring (MIM) in which a limited subset of ions related to particular volatile compounds are 
quantified in any given time period hence increasing sensitivity and measurement precision 
and, as a consequence, sensitivity. FS mode generates a value for each m/z in counts per 
second, whereas MIM converts product ion count rates into actual concentrations using 
predetermined reaction rate constants.50  For FS analysis the mass range used was from m/z 10 
to 200, with each scan taking 185 seconds using the H3O+ and NO+ precursor ions. Mass 




of the SIFT-MS was conducted over a period of 180s per sample using precursor and product 
ion combinations and reaction rate coefficients obtained from the literature (Table 5). 
 
4.5 Statistical Analysis 
Product ion count rates are partly dependent on precursor ion count rates.  This is 
taken into account when calculating volatile chemical concentrations using MIM mode but 
‘raw’ FS mode mass spectra are not directly comparable between analyses because precursor 
count rates vary somewhat between analyses runs.  To allow mass spectra to be compared 
they are ‘normalised’ by dividing the count rate of each m/z by the precursor ion count rate 
(including hydrate) for each spectrum. (Data was analysed using the Statistica statistical 
analysis software (Dell Statsoft, Tulsa, OK, USA) as described in the Results section.  A 
















Table 5: Summary of H3O+ and NO+ product ions derived from specific compounds  








(x 10-9 cm3 s-1) 
Product ions (m/z) Ref. 
Acetone H3O
+  (19, 37, 
55, 73) 3.9 59 (1), 77 (1) 
47 
Formaldehyde H3O
+ (19, 32) 3.4 31 (1), 33 (-100.4), 83 (-100.9) 
51 
Acetaldehyde 
H3O+  (19, 37, 
55, 73) 3.7 45 (1.576), 81 (1.831) 
51 
Hydrogen Sulphide H3O
+  (19, 37, 
55, 73) 1.9 35 (1), 53 (1) 
52 
Propanol NO+ (30, 48) 2.3 59 (1) 46 
Propanal NO+ (30, 48) 3.0 55 (-0.006), 57 (1.0) 47 
Hexanal NO
+ (30, 48) 2.5 





4.8 89 (2.5), 102 (2.0) 
53 
Acetic Acid NO+ (30, 48) 0.9 90 (1) 54 
Isoprene NO+ (30, 48) 1.7 66 (-0.006), 68 (1) 55 
The table describes the precursor and product ions (with the multiplier value for each ion) and the reaction rate 
constant used to calculate gas concentrations using SIFT-MS as described in the referenced papers to which the 























5. Results  
 
5.1 Analysis of traces gases present in headspace of blood obtained from cancer 
patients. 
Volatile chemicals in the headspace of blood plasma obtained from patients with lung, 
breast, or colorectal cancers, and from healthy controls, was analysed using SIFT-MS. The 
MIM and FS modes were used to quantify the headspace concentration of particular gases 
(MIM mode) expected to be found in plasma headspace and/or which had previously been 
shown to be altered in cancer as described in Table 6. The headspace concentration of 
acetaldehyde differed between subject groups considering, in the first instance, both sexes 
combined (C in the Table) (P<0.05; one way ANOVA) with post-hoc analysis indicating 
reduced acetaldehyde concentration in all three patient groups compared to healthy controls 
(Tukey test; P<0.05). Propanal concentration also differed significantly between groups 
(P<0.05) with post-hoc testing indicating significantly increased concentrations in the 
headspace of plasma from patients with breast cancer, but not colorectal or lung cancers, 
compared to healthy controls (P<0.05). Applying a Bonferroni correction resulted in no 
significant differences being detected (Table 6).  The analyses of normalised mass spectra 
obtained using the FS mode (Tables 7 and 8) showed statistically significant differences in the 
rate of formation of a number of product ions formed in the reaction with H3O+ with blood 
headspace.  For many of these significant differences (post-hoc Tukey; P < 0.05) were found in 
all 3 patients groups compared to controls (m/z 63, 85, 89, 103, 104, 119, 121, and 124), some 
in only 2 groups (m/z 42, 51, 69, 86, 102, 107,and 125), and some in only one these being m/z 
60, 70, and 179 in lung cancer only, m/z 45, 81, 99, and 108 in breast cancer only, and m/z 96, 
169, and 170 in colorectal cancer only. For the reaction with NO+ precursor ion many, though 




differences (post-hoc Tukey; P < 0.05) were found in all 3 patients groups compared to controls 
(m/z 114 only), none in only 2 groups, and some in only one these being m/z 90 and 195 in lung 
cancer only, m/z 29, 80, 102, and 116 in breast cancer only, and none in colorectal cancer only.   
Given the large number of simultaneous comparisons a Bonferroni correction was 
applied based on 190 comparisons per precursor ion giving a threshold p-value of 0.0002.56 
This resulted in only m/z 99 from the H3O+ reaction differing between groups for combined 
male and female participants and female only, and m/z 124 with both sexes combined, with no 
significant differences being detected post-Bonferroni for the NO+ reaction.   
Given that gender and age were not matched across groups the effect of each was 
investigated by both including only one sex in the analysis or by directly comparing values in 
males and females within each participant group (Tables 6-11).  For the MIM experiments, 
acetaldehyde concentration was significantly (P < 0.05) lower than healthy controls in both 
male and females, with the exception of females with lung cancer, although the difference was 
more pronounced in men compared with women (Table 6). Indeed, comparison of 
concentrations between men and women showed that acetaldehyde concentration was higher in 
males compared to female healthy controls (t-test; P < 0.05). For propanal no significant 
differences were found between groups when only male or female subjects were included in the 
analysis (P > 0.05). No significant correlations (Table 10) were found between the measured 
volatile chemical concentration except between acetone and age in the healthy control group (P 
< 0.05). Concluding that there was no effect of sex in all compounds except in acetaldehyde.  
For the FS data, segregating by sex retained many statistically significant differences 
with the normalised counts differing between groups more often in females than males (Tables 
7 and 8), although for many significant differences were observed in both sexes. In no case was 




to not differ significantly between group in both the male and female sub-groups.  Comparison 
of normalised count rates between male and female participants in each subject group did 
reveal differences (Tables 7 and 8). (P < 0.05; one way ANOVA).    
The effect of age was investigated using linear regressional analysis (Tables 9-11).  For 
the chemical concentration data collected using MIM acetone levels were weakly (r2 < 0.20) 
correlated to age in the control group only, and malondialdehyde in the breast cancer group 
only; no other significant correlations were observed (Table 9).  For the FS analysis (Tables 10 
and 11) a number of significant correlations were observed although these were mostly weak 
(r2 < 0.20).  No correlations for either the MIM or FS data set were observed following 
application of the Bonferroni correction.   
The product ions which were found to differ between participant groups are 
summarised in Table 12, listed by whether they differed from the control groups in all cancer 
groups, in two out of three, or just in one. The possible identity of the chemical from which 





Table 6: Headspace concentrations of selected volatile chemicals measured using MIM mode SIFT-
MS in male and female in patients with cancer and healthy controls.  
 
The concentrations of the indicated gases were quantified in plasma headspace of samples obtained from patients with breast, 
colorectal, and lung cancers, and from healthy controls. Data are shown as mean PPB ± SD.  C= combined male and female,                 
F= female only, M=male only.   Concentrations were compared between groups using a one-way ANOVA and post-hoc Tukey  
test conducted as appropriate. 1: P<0.05, 2: P<0.01.  Whether the ANOVA was significant after Bonferroni correction (for 30 
comparisons) is indicated (Yes or No).  Concentrations in males and females were compared by t-test, a: P<0.05, b: P<0.01.














C 252.9 ±186.2 202.7 ± 141.0 238.8 ± 210.8 346.6 ± 530.8 F3, 209=1.82 
F 256.1 ± 201.2 202.7 ±141.0 236.6± 121.5 381.6 ± 675.3 F2, 155=1.70 




C 7.6  ± 6.7 7.9  ± 5.6 9. 7  ± 5.1 7.5 ± 5.2 F3,209= 1.06 
F 8.3 ± 6.9 7.9 ± 5.6 11.4 ± 5.7 7.4 ± 5.8 F2, 255= 1.66 




C 13.8 ± 18.9 7.5 ± 4.11 8.2 ± 3.61 9.0 ± 4.91 F3,209= 3.481, no 
F 10.5 ± 5.3a 7.5 ± 4.11 7.8 ± 3.61 9.3 ± 5.6 F2, 255=3.371, no 




C 4.0 ± 2.5 3.9 ± 2.2 4.8 ± 3 4.2 ± 2.2 F3,209= 1.09 
F 3.8 ± 2.1 3.9 ± 2.2 4.6 ± 2.8 4.2 ± 2.4 F2, 255=0.58 




C 21.7 ± 25.7 23.2 ± 18.6 26.7 ± 23.3 27.1 ± 29.2 F3,209=0.52 
F 21.7 ± 27.3 23.2 ± 18.6 29.2± 27.2 27.1 ± 28.6 F2, 255=0.61 




C 20.4 ± 18.9 31.2 ± 24.51 20.9 ± 19.3 21.4 ± 16.3 F3,209= 3.131, no 
F 21.4 ± 20.2 31.2 ± 24.5 26.1 ± 22.7 21.7 ± 16.5 F2, 255=1.97 




C 439.1 ± 1189.8 153.9 ± 228.6 150.9 ± 130 173.1 ± 203.4 F3,209= 2.19 
F 389.5 ± 1118.8 153.9 ± 228.6 170.2 ± 159.3 182.3 ± 199 F2, 255=1.18 
M 699.5 ± 1576.4 NA 132.7 ± 95.9 156.5 ± 217.1 F2, 51=2.08 
  
Malondialdehyde 
C 38.2 ± 21.8 30.6 ± 16.4 33.0± 17.0 40.9 ± 34.7 F3,209= 1.81 
F 39.7 ± 23.1 30.6 ± 16.4 30.0 ± 18.3 43.8 ± 40.2 F2, 255=2.28 




C 34.1 ± 17.7 30 ± 14.0 27 ± 10.2 32.4 ± 14.8 F3,209= 1.79 
F 34.3 ± 18.4 30 ± 14.0 26.2 ± 9.6 33.2 ± 15.2 F2, 255=1.40 




C 10.4 ± 8.3 17.1 ± 16.7 13.5 ± 17.9 17.1 ± 17.6 F3,209= 2.10 
F 10.7 ± 8.3 17.1 ± 16.7 14.6 ± 20.6 16.3 ± 14.1 F2, 255=1.60 




Table 7:  Normalised product ion count rates of the reaction between plasma headspace 
obtained from patients with cancer and healthy controls and H3O+ ions. 





















C 20 ± 30 10 ± 20 10 ± 30 10 ± 20 F3,173= 2.03 
F 20 ± 30 10 ± 201 20 ± 40 4 ± 101 F2,,128=2.951, no 
M 10 ± 20 NA 10 ± 20 10 ± 20 F2,42=0.10 
 
42 
C 100 ± 100 30 ± 1002 40 ± 1002 100 ± 100 F3,173= 5.842, no 
F 100 ± 100 30 ± 1002 30 ± 1002 100 ± 100 F2, 128=7.012, no 
M 100 ± 100 NA 100 ± 100 100 ± 100 F2,42=0.60 
 
43 
C 400 ± 400 200 ± 200 300 ± 300 300 ± 200 F3,173= 2.56 
F 400 ± 400 200 ± 2001 300 ± 1001 400 ± 200 F2,128=3.021, no 
M 400± 200 NA 400 ± 400 300 ± 200 F2,42=0.86 
 
42 
C 100 ± 200 40 ± 402 100 ± 100 100 ± 40 F3,173= 4.212,  no 
F 100 ± 100 40 ± 40 40 ± 40 50 ± 50 F2,128=2.11 
M 400 ± 400c NA 100 ± 2001 100 ± 1001 F2,42=6.381,  no 
 
51 
C 1600 ± 1100 900 ± 5001 1400 ± 2200 1100 ± 5001 F3,173= 3.271,no 
F 1500 ± 1000 900 ± 5002 1300 ± 1200 1100 ± 6002 F2,128=4.112,  no 
M 1900 ± 1500 NA 1700 ± 3200 1000 ± 400 F2,42=0.81 
 
52 
C 30 ± 40 10 ± 20 20 ± 40 10 ± 20 F3,173= 5.04 
F 30 ± 40 10 ± 202 10 ± 302 10 ± 202 F2,128=4.802,no 
M 40 ± 40 NA 30 ± 100 10 ± 20 F2,42=1.10 
 
54 
C 2300 ± 1400 2000 ± 1600 3200 ± 2400 4400 ± 8900 F3,173= 2.48 
F 2000 ± 1200b 2000 ± 1600 2800 ± 1700 5500 ± 119001 F2,128=2.951,  no 
M 3300 ± 1900 NA 3700 ± 3200 3000 ± 1800 F2,42=0.39 
 
56 
C 4700 ± 600 4500 ± 900 4500 ± 700 4700 ± 600 F3,173=1.86 
F 4800 ± 600 4500 ± 900 4700 ± 600 5100 ± 10001 F2,128=2.871, no 
M 4600 ± 400 NA 4300 ± 800 4500 ± 700 F2,42=0.90 
 
60 
C 200 ± 200 100 ± 100 200 ± 200 300 ± 3002 F3,173=4.102, no 
F 200 ± 200 100 ± 1002 200 ± 200 300 ± 2002 F2,128=4.662, no 
M 200 ± 100 NA 200 ± 300 300 ± 300 F2,42=0.51 
 
63 
C 300 ± 500 100 ± 1003 100 ± 2003 100 ± 1003 F3,173= 6.433, no 
F 200 ± 300c 100 ± 1001 100 ± 1001 100 ± 2001 F2,128=2.841, no 
M 800 ± 800c NA 200 ± 3003 200 ± 100 F2,42=10.283, no 
 
69 
C 6800 ± 4500 4400 ± 23001 6000 ± 6800 4700 ± 45001 F3,173= 3.411, no 
F 6100 ± 3000a 4400 ± 23001 4900 ± 33001 4900 ± 24001 F2,128=2.951, no 
M 9700 ± 7700 NA 7400 ± 9700 4600 ± 1700 F2,42=1.97 
 
70 
C 100 ± 100 100 ± 100 100 ± 100 100 ± 1002 F3,173=4.462, no 
F 100 ± 100 100 ± 100 100 ± 100 100 ± 100 F2,128=2.60 























C 400 ± 500 100 ± 1002 200 ± 200 200 ± 100 F3,173= 5.562, no 
F 200 ± 300 100 ± 100 100 ± 100 200 ± 100 F2,128=2.31  
M 800 ± 900b NA 200 ± 2003 200 ± 1003 F2,42=8.333, no 
 
85 
C 2500 ± 4000 300  ± 2003 1100  ± 42003 400  ± 3003 F3,173= 6.333, no 
F 1900 ± 3700a 300 ± 2003 300 ± 2003 500 ± 3003 F2,128=5.733, no 
M 4700 ± 4300a NA 2100 ± 6400 400 ± 3001 F2,42=3.461, no 
 
86 
C 100 ± 200 30 ± 402 100 ± 100 30 ± 403 F3,173=5.512, no 
F 100 ± 200 30 ± 402 20 ± 402 20 ± 402 F2,128=4.432, no 
M 100 ± 200 NA 100 ± 200 30 ± 401 F2,42=3.291, no 
 
89 
C 300 ± 400 100 ± 1003 100 ± 1003 200 ± 4003 F3,173= 5.583, no 
F 300 ± 400 100 ± 1003 100 ± 100 200 ± 200 F2,128=6.523, no 
M 300 ± 400 NA 100 ± 200 300 ± 600 F2,42=0.56  
 
92 
C 500 ± 200 500 ± 200 400 ± 300 500 ± 200 F3,173= 1.46  
F 500 ± 200 500 ± 200 300 ± 2001 400± 200 F2,128=3.001, no 
M 500 ± 200 NA 500 ± 300 500 ± 200 F2,42=0.02  
 
96 
C 400 ± 400 300  ± 300 200 ± 3002 400  ± 300 F3,173= 3.912, no 
F 400 ± 400 300 ± 300 200 ± 3001 400 ± 300 F2,128=3.071, no 
M 400 ± 300 NA 300 ±300 400 ± 400 F2,42=1.15  
 
99 
C 500 ± 500 200 ± 1003 300 ± 200 300 ± 200 F3,173= 8.263, yes 
F 400 ± 400c 200 ± 1001 200 ± 1002a 300 ± 200 F2,128=3.791, no 
M 1100 ± 700c NA 300 ± 2003a 300 ± 2003 F2,42=14.223, yes 
 
100 
C 100 ± 200 30 ± 100 40 ± 100 40 ± 100 F3,173= 2.23  
F 100 ± 100 30 ± 100 20 ± 30 50 ± 100 F2,128=1.35  
M 300 ± 400b NA 100 ± 1001 40 ± 1001 F2,42=3.281, no 
 
102 
C 400 ± 900 100 ± 1001 200 ± 1100 100 ± 1001 F3,173= 3.081, no 
F 300 ± 1000b 100 ± 100 30 ±401 100 ± 50a F2,128=2.981, no 
M 1100 ± 1400 NA 500 ± 1600b 100 ± 100 F2,42=2.51  
 
103 
C 1100 ± 3300 100 ± 1002 100 ± 2002 100 ± 1002 F3,173=4.532, no 
F 1400 ± 3700  60 ± 1001 40 ± 1001 100 ± 1001 F2,128=3.241, no 
M 600 ± 3400 NA 100 ± 300 50 ± 50 F2,42=1.90  
 
104 
C 1000 ± 3000 40 ± 1002 100 ± 1002 100 ± 1002 F3,173= 4.562, no 
F 1100 ± 3200    40 ± 1001 100 ± 100 100 ± 100 F2,128=3.301, no 
M 900 ± 2400 NA 100 ± 100 100 ± 100 F2,42=1.95  
 
107 
C 5100 ± 8100 600 ± 7003 1000 ± 17003 2900 ± 5500 F3,173= 7.653, no 
F 5000 ± 8500 600 ± 7003 800 ± 17003     2500 ± 3300 F2,128=6.563, no 
M 5600 ± 6500 NA 1300 ± 1600 3400 ± 7400 F2,42=1.65  
 
108 
C 200 ± 300 30 ± 1003 100 ± 100 100 ± 200 F3,173= 9.113, no 
F 200 ± 300 30 ± 1003 100 ± 100 100 ± 100 F2,128=9.373, no 




Values shown are mean ± SD of normalized count rates multiplied by 10,000. C= combined male and female, F= 
female only, M=male only.  Only the m/z values which have at least one ANOVA indicating a significant difference 
between groups in the combined, male or female participants are shown; all other ions showed no significant group 
differences.  One-way ANOVA and post-hoc Tukey test were conducted as appropriate.  1: P < 0.05, 2: P < 0.01. 
Whether the ANOVA was significant after Bonferroni correction (for 190 comparisons) is indicated (Yes or No). The 


















C 100 ± 200 100  ± 100 100 ± 100 100 ± 100  F3,173= 5.04 
F 100 ± 200 100 ± 1002 100 ± 1002 100 ± 100 F2,128=4.232, no 
M 100 ± 100 NA 100 ± 100 100 ± 100 F2,42=1.04  
 
119 
C 300 ± 300 200 ± 1002 200 ± 2002 200 ± 1002 F3,173= 4.122, no 
F 300 ± 300 200 ± 100 100 ± 1001 200 ± 100 F2,128=3.231, no 
M 300 ± 300 NA 200 ± 200 200 ± 100 F2,42=2.17  
 
121 
C 3900 ± 11600 40 ± 1002 100 ± 1002 50 ± 1002 F3,173= 4.522, no 
F 3900 ± 12000 40 ± 1001 40 ± 401 40 ± 1001 F2,128=3.271, no 
M 3500± 10900 NA 100 ± 200 100 ± 100 F2,42=1.80 no 
 
122 
C 300 ± 700 20 ± 402 20 ± 402 10 ± 302 F3,173= 4.832, no 
F 200 ± 700 20 ± 401  20 ± 401 10 ± 201 F2,,128=3.401, no 
M 300 ± 800 NA 20 ± 30 10 ± 30 F2,42=2.06  
 
123 
C 200 ± 300 100 ± 100 200 ± 800 70 ± 80 F3,173= 1.85  
F 200 ± 300a 100 ± 1001 100 ± 1001 100 ± 1001 F2,128=3.121, no 
M 400 ± 400 NA 400 ± 1300 100 ± 100 F2,42=1.01  
 
124 
C 50 ± 100 4 ± 103 10 ± 40 10 ± 20 F3,173= 8.373, yes 
F 40 ± 100a 4 ± 102 10 ± 20 10 ± 30 F2,128=5.632, no 
M 100 ± 100a NA 20 ± 502 10 ± 30 F2,42=6.192, no 
 
125 
C 500 ± 600 100 ± 1003 300 ± 700 200 ± 2003 F3,173= 6.533, no 
F 500 ± 600 100 ± 1003 200 ± 1003 200 ± 2003 F2,128=9.423, no 
M 600± 600 NA 400 ± 1100 300 ± 300 F2,42=0.80  
 
126 
C 40 ± 100 10 ± 202 20 ± 100 10  ± 30 F3,173= 3.992, no 
F 40 ± 100 10 ± 202 10 ± 20 10 ± 202 F2,128=3.972, no 
M 40 ± 100 NA 30 ±100 10 ± 40 F2,42=0.79  
 
139 
C 1100 ± 2300 100 ± 100 5800 ± 34200 100 ± 100 F3,173= 1.24  
F 600 ± 1300c 100 ± 1002 100 ± 1002 100 ± 2002 F2,,128=5.082, no 
M 3100 ± 3900 NA 13600 ± 52300 100 ± 100 F2,42=0.85  
 
140 
C 100 ± 100 3 ± 10 400 ± 2000 5 ± 20 F3,173= 1.29  
F 50 ± 100b 3 ± 102 10 ± 40 1 ± 20 F2,128=3.752, no 
M 200 ± 200 NA 800 ± 3100  2 ± 10 F2,42=0.88  
 
169 
C 200 ± 500 30 ± 100 30 ± 501 20 ± 30 F3,173= 3.411,no 
F 200 ± 500 30 ± 100 30 ± 50 20 ± 30 F2,128=2.22  
M 200 ± 300 NA 30 ± 50 20 ± 30 F2,42=3.10  
 
  170 
C 20 ± 100 3 ± 10 3 ± 101 10 ± 30 F3,173=2.871,, no 
F 20 ± 100 3 ± 10 0 ± 0 10 ± 30 F2,,128=2.29  
M 20 ± 40 NA 10 ± 20 10  ± 20 F2,42=0.82  
 
179 
C 10 ± 30 10 ± 20 10 ± 30 30  ± 1001 F3,173=2.811, no 
F 10 ± 20 10 ± 20 5 ± 20 50 ± 1001 F2,128=3.591, no 




Table 8:  Normalised product ion count rates of the reaction between plasma headspace 
obtained from patients with cancer and healthy controls and NO+ ions.  
 



























C 0 ± 0  0 ± 0 0 ± 0 10 ± 30 F3,173= 2.20  
F 0 ± 0 0 ± 0 0 ± 0 10 ± 302 F2,128=3.422, no 
M 0 ± 0 NA 0 ± 0 0 ± 0 Cannot be calculated 
 
29 
C 5000 ± 2000 3900 ± 23002 5700 ± 2000 4900 ± 2300 F3,173= 5.222, no 
F 4800 ± 1900 3900 ± 2300 5700 ± 19002 5000 ± 2200 F2,128=4.222, no 
M 5900 ± 0.22 NA 5600 ± 2200 4800 ± 2500 F2,42=0.82 
 
80 
C 500  ± 500 300 ± 3001 400  ± 500 300 ± 300 F3,173= 2.921, no 
F 500  ± 400a 300 ± 300 200 ± 200b 300 ± 300b F2,128=2.48  
M 900 ± 700a NA 700 ± 700b 300 ± 300 F2,42=2.72  
 
90 
C 200 ± 300 200 ± 200 100 ± 100 300 ± 4001 F3,173= 2.711, no 
F 200 ± 300 200 ± 200 200 ± 300 200 ± 300 F2,128=0.84  
M 300 ± 100 NA 100 ± 100 400 ± 500 F2,42=1.83  
 
102 
C 300 ± 400 200 ± 2001 200 ± 300 200 ± 300 F3,173= 2.871, no 
F 300 ± 400 200 ± 200 100 ± 2001 200 ± 200 F2,128=3.441, no 
M 300 ± 200 NA 200 ± 400 200 ± 400 F2,42=0.16  
 
114 
C 1000 ± 3100 100 ± 4002 100 ± 2002 40 ± 1002 F3,173=4.582, no 
F 1100 ± 3700 100 ± 400 100 ± 300 40 ± 1001 F2,128=3.211, no 
M 800 ± 1600 NA 100 ± 100 40 ± 100 F2,42=2.05  
 
116 
C 300 ± 400 100 ± 2001 200 ± 300 100 ± 200 F3,173= 3.531, no 
F 300 ± 400 100 ± 2001 200 ± 300 100 ± 2001 F2,128=2.921, no 
M 300 ± 600 NA 200 ± 200 100 ± 200 F2,42=0.90  
 
117 
C 500  ± 800 100 ± 100 40700 ± 239200 200 ± 300 F3,173= 1.36  
F 500 ± 800 100 ± 100 70900 ± 316500 200 ± 300 F2,,128=1.94  
M 800 ± 800 NA 400 ± 8001 200 ± 2001 F2,42=3.371, no 
 
119 
C 300 ± 400 100 ± 100 41400 ± 246400 200 ± 300 F3,173=1.36  
F 200 ± 400 100 ± 100 72400 ± 323300 200 ± 300 F2,128=1.94  
M 400 ± 400 NA 100 ± 1002 200 ± 2002 F2,42=5.162, no 
 
128 
C 100 ± 200 20 ± 40 100 ± 200 200 ± 600 F3,173= 1.69  
F 100 ± 200 20 ± 402 30 ± 1002 100 ± 100 F2,128=4.77  























  142 
C 20 ± 100 30 ± 100 100 ± 300 100 ± 500 F3,173= 0.82  
F 20 ± 100 30 ± 100 200 ± 5001 20 ± 100 F2,128=3.121, no 
M 20 ± 40 NA 20 ± 50 200 ± 700 F2,42=0.52  
 
152 
C 100 ± 300 20 ± 100 100 ± 100 100 ± 50 F3,173= 0.95  
F 100 ± 300 20 ± 100 100 ± 100 20 ± 60 F2,128=0.55  
M 20 ± 50 NA 100 ± 1001 10 ± 20 F2,42=3.701, no 
 
157 
C 30 ± 100 30 ± 100 10 ± 30 10 ± 100 F3,173= 1.33  
F 20 ± 50 30 ± 100 100 ± 300 20 ± 80 F2,128=0.55  
M 100 ± 100 NA 0 ± 0 5 ± 202 F2,42=5.252, no 
 
195 
C 3 ± 20 0 ± 0 3 ± 20 40 ± 1002 F3,173= 4.002, no 
F 4 ± 20 0 ± 0 10 ± 302 50 ± 100 F2,128=3.931, no 
M 0 ± 0 NA 0 ± 0 20 ± 70 F2,42=1.08  
 
200 
C 3 ± 20 0 ± 0 10 ± 40 0 ± 0 F3,173=1.79  
F 0 ± 0a 0 ± 0 20 ± 1002 0 ± 0 F2,,128=3.982, no 
M 20 ± 60 NA 0 ± 0 0 ± 0 F2,42=1.98  
Values shown are mean ± SD of normalized count rates multiplied by 10,000.  C= combined male and female, F= 
female only, M=male only.  Only the m/z values which have at least one ANOVA indicating a significant difference 
between groups in the combined, male or female participants are shown; all other ions showed no significant group 
differences.  One-way ANOVA and post-hoc Tukey test were conducted as appropriate.  1: P < 0.05, 2: P < 0.01. 
Whether the ANOVA was significant after Bonferroni correction (for 190 comparisons) is indicated (Yes or No). 























Table 9: Comparison between plasma headspace volatile chemical concentration and 
subject age in patients with cancer, and in healthy controls. 
 











r2 0.10 0.00 0.00 0.04 
P 0.03 0.66 0.96 0.18 
Formaldehyde  
r2 0.01 0.03 0.00 0.01 
P 0.55 0.23 0.74 0.55 
Acetaldehyde 
r2 0.01 0.00 0.00 0.01 
P 0.42 0.74 0.69 0.46 
Hydrogen 
Sulphide  
r2 0.00 0.02 0.05 0.02 
P 0.71 0.37 0.19 0.35 
Propanol 
r2 0.01 0.03 0.02 0.03 
P 0.51 0.22 0.37 0.31 
Propanal 
r2 0.00 0.05 0.01 0.00 
P 0.94 0.10 0.63 0.68 
Hexanal 
r2 0.00 0.01 0.01 0.01 
P 0.77 0.61 0.52 0.55 
Malondialdehyde 
r2 0.05 0.08 0.04 0.00 
P 0.12 0.14 0.26 0.76 
Acetic Acid 
r2 0.02 0.03 0.00 0.01 
P 0.34 0.21 0.87 0.55 
Isoprene 
r2 0.02 0.01 0.00 0.02 
P 0.36 0.50 0.74 0.39 
Headspace concentration of selected compounds was compared with subject age using regressional analysis.   
The squared Pearson correlation coefficient (r2) and the statistical significance (P) is shown.   Correlations which 
















Table 10: Comparison between the rate of product ions formation produced in the 
reaction between plasma headspace and H3O+ ions and subject age in patients with 













41 r2 0.06 0.01 0.00 0.01 
P 0.11 0.41 0.92 0.48 
42 r2 0.02 0.01 0.19 0.01 
P 0.37 0.50 0.01 0.48 
43 r2 0.01 0.01 0.19 0.00 
P 0.48 0.42 0.01 0.99 
45 r2 0.04 0.02 0.10 0.00 
P 0.15 0.29 0.06 0.80 
47 r2 0.05 0.03 0.12 0.04 
P 0.11 0.24 0.04 0.19 
48 r2 0.04 0.01 0.12 0.0 
P 0.18 0.53 0.04 0.95 
49 r2 0.12 0.0 0.11 0.17 
P 0.02 0.81 0.05 0.012 
50 r2 0.00 0.01 0.02 0.02 
P 0.94 0.53 0.40 0.41 
51 r2 0.01 0.02 0.10 0.07 
P 0.40 0.36 0.10 0.13 
52 r2 0.03 0.09 0.13 0.11 
P 0.24 0.04 0.03 0.03 
54 r2 0.15 0.0 0.05 0.03 
P 0.012 0.66 0.19 0.31 
56 r2 0.05 0.00 0.03 0.03 
P 0.13 0.87 0.34 0.24 
60 r2 0.01 0.00 0.19 0.00 
P 0.47 0.90 0.01 0.86 
63 r2 0.05 0.07 0.09 0.00 
P 0.11 0.07 0.08 0.82 
69 r2 0.00 0.04 0.11 0.01 
P 0.66 0.16 0.05 0.65 
70 r2 0.00 0.04 0.08 0.00 
P 0.90 0.16 0.10 0.93 
81 r2 0.01 0.05 0.02 0.00 
P 0.62 0.12 0.41 0.82 
85 r2 0.00 0.03 0.11 0.03 
P 0.88 0.22 0.05 0.29 
86 r2 0.04 0.01 0.10 0.04 
P 0.18 0.53 0.06 0.20 
89 r2 0.00 0.02 0.01 0.00 
P 0.76 0.33 0.55 0.81 
91 r2 0.02 0.00 0.03 0.03 
P 0.35 0.87 0.33 0.25 
92 r2 0.01 0.00 0.03 0.01 




       
The rate of product ion formation was compared with subject age using regressional analysis.  The squared 
Pearson correlation coefficient (r2) and the statistical significance (P) is shown. Only those ions differing in 




















96 r2 0.05 0.00 0.24 0.00 
P 0.13 0.76 0.00 0.69 
99 r2 0.01 0.01 0.01 0.00 
P 0.51 0.59 0.60 0.72 
100 r2 0.00 0.00 0.09 0.02 
P 0.86 0.76 0.07 0.32 
102 r2 0.00 0.01 0.13 0.00 
P 0.68 0.41 0.03 0.89 
103 r2 0.02 0.01 0.10 0.04 
P 0.30 0.58 0.10 0.22 
104 r2 0.02 0.01 0.01 0.01 
P 0.32 0.51 0.68 0.65 
107 r2 0.06 0.12 0.05 0.00 
P 0.08 0.01 0.20 0.90 
108 r2 0.02 0.01 0.03 0.00 
P 0.28 0.44 0.34 0.94 
109 r2 0.00 0.01 0.04 0.05 
P 0.88 0.42 0.26 0.14 
117 r2 0.04 0.00 0.00 0.02 
P 0.18 0.67 0.72 0.36 
119 r2 0.02 0.01 0.14 0.01 
P 0.31 0.61 0.03 0.54 
121 r2 0.03 0.01 0.03 0.00 
P 0.27 0.44 0.36 0.86 
123 r2 0.00 0.00 0.12 0.05 
P 0.79 0.67 0.04 0.17 
124 r2 0.00 0.04 0.02 0.01 
P 0.83 0.15 0.45 0.57 
125 r2 0.01 0.22 0.10 0.00 
P 0.49 0.00 0.07 0.66 
126 r2 0.01 0.06 0.11 0.00 
P 0.61 0.09 0.05 0.68 
139 r2 0.01 0.00 0.12 0.02 
P 0.44 0.74 0.04 0.38 
140 r2 0.00 0.01 0.12 0.03 
P 0.73 0.59 0.04 0.28 
169 r2 0.04 0.00 0.00 0.05 
P 0.18 0.89 0.91 0.15 
170 r2 0.01 0.00 0.01 0.03 
P 0.59 0.81 0.53 0.29 
179 r2 0.06 0.01 0.00 0.01 




Table 11: Comparison between the rate of product ion formation produced in the 
reaction between plasma headspace and NO+  ions and subject age in patients with 














26 r2 0.00 0.00 0.00 0.03 
P 0.00 0.00 0.00 0.25 
29 r2 0.00 0.04 0.00 0.00 
P 0.08 0.19 0.83 0.83 
80 r2 0.01 0.06 0.03 0.01 
P 0.55 0.09 0.32 0.44 
90 r2 0.02 0.03 0.21 0.00 
P 0.34 0.26 0.01 0.99 
102 r2 0.01 0.00 0.10 0.00 
P 0.57 0.71 0.06 0.69 
114 r2 0.03 0.03 0.03 0.00 
P 0.27 0.22 0.35 0.95 
116 r2 0.01 0.07 0.00 0.02 
P 0.59 0.07 0.69 0.43 
117 r2 0.00 0.01 0.02 0.00 
P 0.78 0.52 0.47 0.93 
119 r2 0.01 0.01 0.02 0.02 
P 0.42 0.45 0.47 0.35 
128 r2 0.06 0.02 0.00 0.01 
P 0.11 0.32 0.81 0.54 
145 r2 0.01 0.01 0.03 0.04 
P 0.52 0.51 0.34 0.22 
152 r2 0.01 0.01 0.00 0.09 
P 0.48 0.58 0.96 0.06 
157 r2 0.01 0.05 0.00 0.02 
P 0.44 0.13 0.81 0.39 
195 r2 0.00 0.00 0.04 0.01 
P 0.00 0.00 0.27 0.61 
200 r2 0.00 0.00 0.00 0.00 
P 0.90 0.00 0.83 0.00 
The rate of product ion formation was compared with subject age using regressional analysis.   
The squared Pearson correlation coefficient (r2) and the statistical significance (P) is shown.  Only those ions  














Table 12: Summary of H3O+ and NO+ product ions and compounds derived from study #1.  
Groups 
Product 
ions Precursor ion Possible chemical identity from literature 
Ref. 
(m/z) 
In all groups 
63 H3O+ dimethyl sulphide 52 
85 H3O+ pentanoic acid, methanthiol  52’54 
89 H3O+ methyl propionate, ethyl acetate, butyric acid, malondialdehyde, putrescine, pentanol 
47,53,54,57,58 
103 H3O+ 
pentanoic acid, trimethylacetic acid, ethyl 
propionate, methyl butyrate, cadaverine 
54,57,58 
104 H3O+ methyl acetate 57 
119 H3O+ hexanal,  hexanone 47 
121 H3O+ propyl benzene, phenylethanone, pentanoic acid 43’54’59 
122 H3O+ phenylethanol 59 
114 NO+   
In two groups  
42 H3O+    
51 H3O+ methanol 46 
69 H3O+ pentanal, methanol 46 
86 H3O+ cadaverine 58 
102 H3O+  
 
107 H3O+ pentanol, xylene, butyric acid, ethyl acetate, putrescine, benzaldehyde  
47,54,57,58 
125 H3O+ pentanol, butyric acid 47,54 
In Lung 
disease group 
60 H3O+    
70 H3O+ 2-methyl-1-butanol 60 
179 H3O+    
90 NO+ acetic acid  54,57 
195 NO+    
In Breast 
disease group 
45, 81 H3O+ acetaldehyde 47 
99 H3O+ hexenal 47 
108 H3O+    
124 H3O+ spermidine  
126 H3O+  58 
57 NO+ 
Propanal, 2-methy-2-propanol, octanol, 





80 NO+    
102 NO+ butanone, malondialdehyde, acrylic acid 47,53,54 
116 NO+ pentanone, hydroxybutyric acid 47’61 
In Colorectal 
disease group 
96 H3O+    




  The ions listed are those found to differ significantly between participant groups (combined sexes) as described in 
Table 7 and 8, including the number of groups the differed in compared to healthy controls.  The possible chemical 




5.2 Investigation of putative cancer markers in healthy controls. 
 
In the previous experiment a series of putative cancer markers, in the form of SIFT-
MS product ions, were identified by means of analysing blood headspace obtained from 
patients with cancer.  The first step in determining whether these have utility in cancer 
diagnosis using breath analysis is to determine whether they are present in breath. 
Furthermore, even if they are present in breath the precise relationship between blood and 
breath concentrations needs to be determined. As such breath and blood headspace was 
compared in a group of healthy controls. Participants provided a sample of blood and nasal 
breath, the normalised count rates of the putative markers ions quantified in blood 
headspace (and a water headspace control) and nasal air (and an ambient air control), and 
the count rates compared (Tables 13 and 14).    
The mean values for each product ion were compared between the two groups to 
get the correlation between blood and breath and as illustrated in Table 15.  Comparing the 
controls (water headspace or ambient air) to their respective biological samples showed 
that only some ions showed values significantly higher than these control samples.  
Specifically, for H3O+ reaction with blood headspace products of m/z 45, 60, 81, 99 and 
169 differed significantly (t-test; P < 0.05) from controls but m/z 70, 96, 108, 124, 126, 
170, and 179 did not; for nasal breath m/z 60, 70, 81, 99, 108, 126 and 179 differed from 
controls (P < 0.05) but m/z 45, 96, 124, 169, and 170 did not.  A similar situation was 
evident for the NO+ reaction products with only m/z 90 differing significantly from 
controls in blood headspace (P < 0.05) while m/z 29, 57, 80, 102, 116 and 195 did not.  For 
nasal breath m/z 57, 90, 102 and 116 differed from ambient air (P < 0.05), while m/z 29, 




108, 126, and 179 formed in the reaction with H3O+ differed significantly (paired t-test; P 
< 0.001) between blood headspace and breath, while m/z 90, 102 and 116 from the reaction 
with NO+ ions differed between blood headspace and breath (paired t-test; P < 0.05).  
Finally, the ratios between the mean normalised ions count rates deriving from blood 
headspace and nasal breath were calculated and observed to vary widely between ions. 
Normalised ion count rates for nasal breath and blood headspace were also 
compared using correlational analysis (Table 15).  For H3O+ reaction products normalised 
ion count rates correlated between breath and blood headspace for product ion m/z 170, 





Table 13: Quantification of putative cancer marker products formed in the reaction with 


















45 121 ± 57 530 ± 2343 256 ± 148 413 ± 575 0.78 
60 178  ± 50 682  ± 3273 266 ± 158 750 ± 4103 1.10 
70 35 ± 53 49 ± 107 43 ± 31 220 ± 863 4.49 
81 121  ± 75 462 ± 2043 101 ± 54 281 ± 1381 0.61 
96 147  ± 76 2365  ± 6718 288 ± 207 410 ± 280 0.17 
99 219  ± 98  502 ± 3632 158 ± 54 250 ± 711,c 0.50 
108 36  ± 29 46 ± 56 193 ± 125 445 ± 293 3,c 9.67 
124 26  ± 28 19  ± 53 25  ± 30 58  ± 125 3.05 
126 22  ± 24 30  ± 47 36 ± 26 255 ± 2273,c 8.50 
169 70 ± 57 125 ± 942 48 ± 43 103 ± 305 0.82 
170 59  ± 34 45 ± 24 74 ± 45 86 ± 26c 2.15 
179 6  ± 18 5  ± 16 77 ± 55 179 ± 1782,c 35.8 
 
Blood and nasal breath were obtained from 30 healthy controls.  The formation rate of the ions of interest (Table 12) 
were quantified using SIFT-MS in MIM mode in blood headspace, water headspace (for comparison with blood), 
and breath and ambient air (for comparison with breath).  Values shown are mean normalized count rates multiplied 
by 10000 ± SD.  Water and blood headspace, or ambient air and breath, were compared using a t-test with the 
statistical significance shown (1: P < .05, 2: P < 0.01, 3: P < 0.001).  Breath and blood headspace were also 
compared using a paired t-test (a: P < 0.05, b: P < 0.01, c: P < 0.001).   The ratio of mean blood headspace ion 




















Table 14: Quantification of putative cancer marker products formed in the reaction with 


















29 23588  ± 2847 22847 ± 4509 24888 ± 7307 22230 ± 7592 0.97 
57 81 ± 27 83 ± 30 59  ± 18 126 ± 441 1.52 
80 144 ± 121 138 ± 127 10 ± 39 22 ± 370 0.17 
90 143 ± 81 240 ± 2281 504 ± 264 1017 ± 4763,c 4.24 
102 50  ± 18 78 ± 64 99 ± 83 155 ± 821,c 1.99 
116 102 ± 45 118 ± 36 157 ± 134 2176± 15323,c 18.44 
195 6 ± 21 14  ± 37 4 ± 20 12 ± 42 0.86 
 
Blood and nasal breath were obtained from 30 healthy controls.  The formation rate of the ions of interest (Table 12) 
were quantified using SIFT-MS in MIM mode in blood headspace, water headspace (for comparison with blood), 
and breath and ambient air (for comparison with breath).  Values shown are mean normalized count rates multiplied 
by 10000 ± SD.  Water and blood headspace, or ambient air and breath, were compared using a t-test with the 
statistical significance shown (1: P < .05, 2: P < 0.01; 3: P < 0.001). Breath and blood headspace were also 
compared using a paired t-test (a: P < 0.05. b: P < 0.01, c: P < 0.001). The ratio of mean blood headspace ion 


























Table 15: Correlational analysis of normalised product ion count rates in the reaction with 












45 0.04 0.83 
60 0.28 0.14 
70 0.02 0.92 
81 0.24 0.20 
96 -0.12 0.52 
99 0.19 0.31 
108 0.08 0.67 
124 0.03 0.87 
126 0.04 0.84 
169 -0.12 0.52 
170 0.53 0.00 
179 0.03 0.87 
NO+  
29 0.66 0.00 
57 0.20 0.30 
80 0.11 0.55 
90 0.20 0.29 
102 -0.03 0.87 
116 0.38 0.04 
195 0.29 0.11 
 
The normalised count rates of various SIFT-MS product ions generated in the reaction between 
H3O+ or NO+ ions and blood headspace or nasal air obtained from 30 healthy controls were 
compared using linear regression.  The Pearson correlation coefficients and p-values are shown.  










The major findings of my thesis are that SIFT-MS can be used to identity putative 
biomarkers of cancer including those that may be markers of only one type of cancer, 
thereby support my first and second hypothesis which are the volatome of blood headspace 
differ between cancer and control groups, and one or more of the VC changes in 
abundance are limited to a single type of cancer.  Moreover, some of these markers are 
present in the human breath of healthy controls which suggest the potential of breath 
testing for cancer diagnostics, in support of my third hypothesis that these VC present in 
breath as well as blood headspace.  
I did, however, find that the correlation between blood headspace and breath was 
generally poor in terms of product ion formation rates suggesting that VCs in the 
bloodstream may not exert a large influence over the concentration of the same VC in the 
airways.  This raises the question of whether such breath markers are useful for cancer in 
general, or should just be aimed at the diagnosis of lung cancer and perhaps other 
pulmonary diseases.   
 
6.1 SIFT-MS product ions which may be cancer biomarkers. 
In this thesis I explored the question of whether the volatome of blood headspace is 
influenced by the person having cancer when compared to that of healthy controls, and 
whether one or more of the VC changes in abundance will be limited to a single type of 
cancer rather than a general marker of the disease.  Considering some common breath 
compounds and a full spectral analysis of product ions formed in the reaction of trace gases 




four participant groups (see Table 12).  Although the groups were not sex-matched I found 
little evidence of an effect of sex upon product ion formation rates and hence collected the 
results I obtained using combined male and female participants.  Although I had age 
matched my participants I also investigated the effect of age on my results but found little 
evidence of there being any effect  
The large number of ions identified by my analysis may at least partly relate to the 
number of simultaneous comparisons being high (over both precursor ions there were 380 
product ions considered).  That is, the number of ions quantified using this type of spectral 
analysis is not based on a specific hypothesis regarding a particular ion, but rather includes 
all possible product ions over the range m/z 10 – 200.  Indeed, applying a ‘Bonferroni’ 
correction, which divides the generally accepted statistical significance level of 0.05 
amongst all the comparisons, resulted in only m/z 99 from the H3O+ reaction being 
considered significantly different between groups (see Tables 8 and 9) (m/z 124 from the 
H3O+ reaction differed when only males were included).  The Bonferroni correction has 
been criticised as being overly conservative, and frequently inappropriate,62 when 
considering a hypothesis such as that in this thesis, that is one which is not directed at a 
particular ion, but rather that any ion is a biomarker of cancer, and hence does not rule out 
that some of the significantly altered ion count rates do indeed differentiate cancer from 
controls.  However the method I employed using full spectrum analysis can be viewed as 
lacking statistical power and would require much larger sample sizes to result in definitive 




However, it is worth considering what the potential identity of these ions are, compare 
them to what others have found, and consider their biological plausibility, that is whether it 
is likely that a human cell, normal or cancer, would generate such a biomarker.  A wide 
variety of compound classes emerge from the SIFT-MS analysis including alcohols, organic 
acids, polyamines, aldehydes, sulphides, and esters, identified by comparing the product 
ions I have identified as possible cancer biomarkers, with the SIFT-MS spectra for known 
compounds described in the literature (see Table 12).  As can be seen from the Table many 
ion products can originate from multiple compounds due to isobaric or isomeric compounds 
frequently possessing overlapping mass spectra.  Comparing the possible chemicals 
identified in Table 12 to the expected ions from biomarkers identified in other studies 
described in the Introduction (Tables 1 and 2) shows some commonality, with hexanal (m/z 
119 with H3O+)  having been associated with the presence of cancer in two or more other 
studies16,33,35, while dimethyl sulphide (m/z 63 with H3O+)16, propyl benzene (m/z 121 with 
H3O+)33, methanol (m/z 51 and 69 with H3O+)36 and xylene (m/z 107 with H3O+)39 have been 
identified in at least one other study. It seems unlikely that esters, such as ethylacetate, are 
the true identity of these ions given that metabolic processes capable of producing are 
unknown.  The significance of alcohol changes is unclear given that longer-chain alcohols 
like pentanol most likely derive from gut microflora,63,64 although this may indicate 
disordered gut function in patients, as would changes in the concentration of propionic acid - 
another gut derived compound.65’66 Compounds such as cadaverine and putrescine generally 
occur in putrefaction but have been reported to  possess altered abundance in patients with 
cancer, possibly relating to necrosis occurring in the tumour or surrounding tissue.67,68 The 




(Table 12) and are of note since both classes of compounds can derive from lipid 
peroxidation, which may change subsequent to altered oxidative stress in cancer.23 Notably 
other authors have reported altered abundance of this compound class in cancer which lends 
support to the possibility that these ions are true markers of, at least, symptomatic cancer.35, 
40,69  It should be pointed out, however, that increased oxidative stress is expected in cancer 
while the data in Tables 7-9 indicate that although propanal concentrations were increased in 
patients with breast cancer, acetaldehyde, and the production rates of ions which may derive 
from pentanal and malondialdehyde, were decreased in one or more cancer groups contrary 
to the hypothesised pathophysiological mechanism.  It is presently unclear as to the reason 
for apparently reduced aldehyde concentrations, although further study of what occurs to the 
abundance of these chemicals during the progression of cancer may shed some light on this 
discrepancy.  Indeed, this study, and others like it, are only conducted using patients whose 
disease are advanced enough to have received a clinical diagnosis of cancer raises the 
problem, discussed in the Introduction, that the altered volatome may be due to 
physiological effects occurring secondary to the primary pathophysiological mechanisms 
and therefore be of no use for the diagnosis of cancer in its pre-symptomatic stage.  Without 
a prospective study being carried out it is not possible to answer this question in any 
definitive way.  However, it is less likely that ions, the abundance of which were changed in 
only one type of cancer, are due to general changes in illness associated with cancer such as 
cachexia, although this does not rule out secondary effects associated with just one type of 
tumour.  Although not conclusive of being associated with a primary pathophysiological 
process I decided to pursue further experiments only with those ions which were identified 




6.2 Putative cancer markers in breath and blood 
Although blood based biomarkers are of interest, mass screening using them would 
require each persons to donate a sample of blood.  Even if using ‘pin prick’ types of 
collection this is unlikely to be used by a significant number of people in good health due to 
the costs, pain and infection risk associated with blood collection.  Breath analysis 
overcomes these difficulties and, as such, I investigated whether the ions I identified in my 
first study with blood headspace could also be produced in during reactions between breath 
and H3O+ or NO+.   
For my initial investigation I utilised healthy controls, and therefore my study was 
unable to detect the breath production of trace-gas derived ions, which only occur in cancer.  
However, since my first study frequently observed decreased ion production rates in cancer, 
this possibility is less likely for many of the product ions under investigation.  My first 
question was whether the formation rate of product ions deriving from breath could be 
differentiated statistically from ambient air samples.  For many of the putative marker ions 
this was indeed the case which indicates that these ions are likely to be at least partly derived 
from endogenously produced compounds.  Of course a failure to differentiate breath from 
ambient does not mean there are no endogenous sources of these ions, merely that ambient 
air also contains higher quantities of these chemicals making them unsuitable for use as 
breath based biomarkers.  For comparison I also tried to differentiate blood headspace from 
water headspace and found that not all ion count rates differed significantly from this control 
sample.  This is surprising given that these ions were identified using plasma samples in 
study 1.  A comparison to a water headspace was not carried out for the first study, however, 




either.  However this seems unlikely given that differences were observed between groups of 
participants, the very reason these ions were chosen for further study.  Study 1 and study 2 
differed slightly in that whole blood was used in the latter and plasma in the former, 
although it is not immediately obvious why this would explain any differences between 
each.  Alternatively, samples in study 2 were freshly collected and analysed immediately, 
while study 1 plasma samples were frozen and stored at -80°C for over a year before 
analysis.  Conceivably a storage effect could also play a role given that others have observed 
degradation of samples stored at anything above liquid nitrogen temperatures.71,72’73 
Nevertheless, it remains notable that many of the putative markers identified using blood 
headspace are also present in human breath and could therefore be used as breath-based 
cancer markers. 
The use of breath analysis to detect cancers occurring out within the pulmonary 
system also necessarily requires that breath concentrations of the marker are directly 
correlated with the bloodstream given that the circulatory system is the means for the VC 
marker to get into the breath.   A significant correlation was observed for the NO+ reaction 
product 116, potentially being pentanone, and the H3O+ reaction product m/z 170 (which 
matches no known ion product in the literature), indicating that concentrations in blood and 
breath are likely related.  The other product that was found to be correlated (NO+ product 
ion m/z 29) could be due to miscounting of the precursor ion m/z 30 as 29.  That is that the 
correlation is due to an artefact related of the mass resolution of the mass spectrometer given 
that m/z 30 is being counted as both m/z 30 and 29.  This conclusion is supported by the fact 
that m/z 29 was not formed at greater rates that that of the control sample in neither blood 




putative cancer marker product ions were not significantly correlated between blood and 
breath.  This is a surprising finding considering that these samples were collected and 
analysed at the same time from the same participants (see Table 15).  No such correlation 
would be expected, of course, for ions, which are not present above control levels (water 
headspace or ambient air) for either breath and/or blood (e.g. the H3O+ reaction product m/z 
108 or the NO+ product m/z 102).  In addition reaction products found in very low 
concentrations (e.g. the H3O+ reaction product m/z 57) may not be quantified with sufficient 
precision to result in a correlation being observed with the sample size used (n=30).  That 
being said, the lack of correlation for some higher abundance ions, such as the H3O+ reaction 
product m/z 60 or the NO+ reaction product m/z 90, is unlikely to be due to these 
measurement effects. It is possible that blood concentrations actually do not predict breath 
concentrations implying that most of these product ions are derived from gases originating 
somewhere in the airways and not from the circulation.  Such a possibility is consistent with 
the large range in relative abundance between breath and blood fractions for each ion (see 
Table 14 and 15).  These ratios ranged from below unity (blood > breath) to well above 
(breath > blood) again suggesting that no strong relationship exists between blood and 
breath fractions in terms of trace gases.  In other words, that breath trace gases are much 
more dependent upon gases originating in the airways than those elsewhere in the body.  
While for some compounds, such as acetone or isoprene, a bloodstream source may be likely 
although certainly not proven, my data is reminiscent of the finding that many compounds 
found in mouth-collected breath mainly originate in the oral cavity.22,23 Given that I used 
nasal rather than mouth breath, a fraction which minimises the contribution of the oral 




trace gases in nasal air mainly originate elsewhere in the airway.  While measurement 
sensitivity and precision problems described above certainly leave such a conclusion open to 
challenge, my data do suggest that (a) identifying putative breath-based non-airway cancer 
markers using blood samples may not be a useful strategy, and (b) that using breath analysis 
to diagnose cancers other than those within the airway will not be possible.   On the other 
hand breath analysis is suitable for diagnosis of airway conditions as has already been 
shown for airway inflammation (ethane and NO+) and infection (hydrogen cyanide).20.30 
 
6.3 Conclusion and Perspectives 
In conclusion my data suggest that the use of SIFT-MS to identify putative disease 
biomarkers present in the blood stream has some value although the full mass spectrum 
approach I used is likely to generate many false positives and would require the use of 
larger sample size.  My data also suggest that screening blood samples to identify markers 
that will ultimately be applied to breath diagnostic testing is of limited value given that the 
relationship between bloodstream volatile chemicals and those in the breath is, at best, 
weak.  Future work using breath analysis to identify disease biomarkers and apply those to 
the screening and diagnosis of illness, including those for lung cancer, should therefore 
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